Dontula R, Dinasarapu AR, Chetty C, Pannuru P, Engelhard H, Ozer H and Lakka S MicroRNA 203 modulates glioma cell migration via Robo1/ERK/MMP-9 signaling. Genes and Cancer, 2013. Full Article
Villano JL, Williams LE, Watson KS, Ignatius N, Wilson MT, Valyi-Nagy T, Michaels EA, Engelhard HH: Delayed response and survival from NovoTTF-100A in recurrent GBM. Medical Oncology 30 (1): 338-339, 2013.
McCarthy BJ, Shibui S, Kayama T, Miyaoka E, Narita Y, Murakami M, Matsuda A, Matsuda T, Sobue T, Palis BE, Dolecek TA, Kruchko C, Engelhard HH, Villano JL: Primary CNS germ cell tumors in Japan and the United States: An analysis of 4 tumor registries. Neuro-Oncology 14 (9):1194-2000, 2012.
Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbalý V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012 Sep;48(14):2192-202. doi: 10.1016/j.ejca.2012.04.011. Epub 2012 May 18.
Engelhard HH, Villano JL, Porter KR, Stewart AK, Barua M, Barker FG II, Newton HB: Clinical presentation, histology and treatment in 430 patients with primary tumors of the spinal cord, spinal meninges or cauda equina. Journal of Neurosurgery Spine 13 (1):67-77, 2010.
Villano JL, Virk IY, Ramirez V, Propp JM, Engelhard HH, McCarthy BJ: Descriptive epidemiology of CNS germ cell tumors: Non-pineal analysis. Neuro-Oncology 12 (3):257-64, 2010.
Claus EB, Abdel-Wahab M, Burger PC, Engelhard HH, Ellison DW, Gaiano N, Gutmann DH, Heck DA, Holland EC, Jallo GI, Kruchko C, Kun LE, Maria BL, Rumboldt Z, Seminara D, Spinella GM, Stophel L, Wechler-Reya R, Wrensch M, Gilbertson RJ: Defining future directions in spinal cord tumor research: Proceedings from the National Institutes of Health workshop report. Journal of Neurosurgery Spine 12 (2):117-21, 2010.
Descriptive epidemiology of central nervous system germ cell tumors: nonpineal analysis.Villano JL, Virk IY, Ramirez V, Propp JM, Engelhard HH, McCarthy BJ.Neuro Oncol. 2010 Mar;12(3):257-64. Epub 2009 Dec 21.PMID: 20167813 [PubMed - indexed for MEDLINE] Full PMC Article
Williams KA Jr., Kouloumberis P, Engelhard HH: Subacute subdural hematoma in a 45 year-old woman with no significant past medical history after a roller coaster ride. American Journal of Emergency Medicine 27 (4): 517 e5-6, 2009.
Villano JL, Mlinarevich N, Watson KS, Engelhard HH, Anderson-Shaw L: Aggression in a patient with primary brain tumor: Ethical implications for best management. Journal of Neuro-Oncology 94 (2): 293-296, 2009.
Villano JL, Heery C, Slavin KV, Engelhard HH: Unusual CNS presentation of thyroid cancer. Accepted for publication, 2009.
Malignant pineal germ-cell tumors: an analysis of cases from three tumor registries.Villano JL, Propp JM, Porter KR, Stewart AK, Valyi-Nagy T, Li X, Engelhard HH, McCarthy BJ. Neuro Oncol. 2008 Apr;10(2):121-30. Epub 2008 Feb 20.PMID: 18287340 [PubMed - indexed for MEDLINE] Full PMC Article
Guzman G, Oh S, Shukla D, Engelhard HH, Valyi-Nagy T: Expression of entry receptor nectin-1 of herpes simplex virus 1 and/or herpes simplex virus 2 in normal and neoplastic human nervous system tissues. Acta virologica 50 (1): 59-66, 2006.
Barshes N, Demopoulos A, Engelhard HH: Anatomy and physiology of the leptomeninges and CSF space. In Abrey LE, Chamberlain MC, Engelhard HH (eds.) Leptomeningeal Metastases. New York: Springer, 2005, pp. 1-16
Engelhard HH, Corsten L: Leptomeningeal metastasis of primary central nervous system (CNS) tumors. In Abrey LE, Chamberlain MC, Engelhard HH (eds.) Leptomeningeal Metastases. New York: Springer, 2005, pp. 71-86
Engelhard HH, Valyi-Nagy T: Biology of the blood-brain and "blood-brain tumor" barriers. In Newton H (ed.) Handbook of Brain Tumor Chemotherapy. San Diego: Elsevier Publishers, 2005.
Jho DH, Engelhard HH, Gandhi R, Chao J, Babcock T, Ong E, Espat NJ: Ciliary neurotrophic factor upregulates ubiquitin-proteasome components in a rat model of neuronal injury. Cytokine 27 (6): 142-151, 2004.
Genomic expression discovery predicts pathways and opposing functions behind phenotypes.Fathallah-Shaykh HM, He B, Zhao LJ, Engelhard HH, Cerullo L, Lichtor T, Byrne R, Munoz L, Von Roenn K, Rosseau GL, Glick R, Sherman C, Farooq K. J Biol Chem. 2003 Jun 27;278(26):23830-3. Epub 2003 Apr 16.PMID: 12700229 [PubMed - indexed for MEDLINE] Full Article
Engelhard HH, Stelea A, Mundt A: Oligodendroglioma: Clinical features, treatment and prognosis. Surgical Neurology 60 (5): 443-456, 2003.
Mathematical modeling of noise and discovery of genetic expression classes in gliomas.Fathallah-Shaykh HM, Rigen M, Zhao LJ, Bansal K, He B, Engelhard HH, Cerullo L, Roenn KV, Byrne R, Munoz L, Rosseau GL, Glick R, Lichtor T, DiSavino E.Oncogene. 2002 Oct 17;21(47):7164-74.PMID: 12370806 [PubMed - indexed for MEDLINE] Full Article
Antisense Oligodeoxynucleotide Technology: Potential Use for the Treatment of Malignant Brain Tumors.Engelhard HH. Cancer Control. 1998 Mar;5(2):163-170.PMID: 10761027 [PubMed - as supplied by publisher] Full Article
Engelhard HH, Lu Y, Rayfield C, Yue L, Lakka S, Mahmud N. Heterogeneity of HDAC3 expression and its modulation by valproic acid in glioblastoma cells. J Clin Oncol 31, 2013 (suppl; abstr e13038).
Wong ET, Villano JL, Engelhard HH, Ram Z, Gutin PH: Analysis of the response profile to NovoTTF-100A Treatment in patients with recurrent GBM: Time to effect, response duration and transient progression in the EF-11 Phase III trial. Neuro-Oncology 14 (Suppl 6): vi65-vi85, 2012.
"Characteristics of a Human Glioblastoma Cell Line (E297) that is Tumorigenic in Immunocompetent Rats"
"Precise Brain Tumor Volume Determinations Using a Personal Computer"
"NFkB, p65(Re1A), is Commonly Expressed by Gliomas and Essential for Glioma Cell Survival" (pdf file)
Stupp R, Kanner A, Engelhard H, Heidecke V, Taillibert S, Lieberman F, Dbaly V, Kirson ED, Palti Y, Gutin PH: A Prospective, Randomized, Open Label, Phase III Clinical Trial of NovoTTF-100A Versus Best Standard of Care Chemotherapy in Patients with Recurrent Glioblastoma. Presented at the Annual Meeting of the American Society for Clinical Oncology. Chicago, Illinois, June 2010.
Stupp R, Kanner A, Engelhard H, Heidecke V, Taillibert S, Lieberman F, Dbaly V, Kirson ED, Palti Y, Gutin PH: A prospective, randomized, open label, phase III clinical trial of novoTTF-100A vs best standard of care chemotherapy in patients with recurrent glioblastoma. Presented at the 9th Meeting of European Association of Neuro-Oncology. Maastricht, Netherlands, September 2010
Engelhard HH, Walters L, Watson KS, Mlinarevich N: Histone Deacetylase Inhibitors Are Appropriate Therapeutic Agents for CED for Malignant Glioma. Presented at the 1st International Meeting of the Society for CNS Interstitial Delivery of Therapeutics. Cleveland, Ohio, September 2009.
McCarthy BJ, Ramirez V, Propp JM, Engelhard HH, Villano JL: Descriptive Epidemiology of Non- Pineal CNS Germ Cell Tumors. Presented at the 13th International Symposium on Pediatric Neuro-Oncology. Chicago, Illinois, June 2008.
Engelhard HH: What Do We Know About Spinal Cord Tumors? – The Role of Surgery. Presented at the NIH Workshop on Spinal Cord Tumors. Bethesda, MD, February, 2007.
Zhou XJ, Leeds NE, Engelhard HH: Quantitative Assessment of Brain Tumor Invasion Using a Fiber Coherence Index. Presented at the Annual Meeting of the International Society for Magnetic Resonance in Medicine. Calgary, Canada, April 2005.
Engelhard HH, Porter KR, Fakhoury F, Barua M, Barker F II: Clinical Presentation, Histology and Treatment of 431 Patients with Primary Tumors of the Spinal Cord, Spinal Meninges or Cauda Equina. Presented at the Annual Meeting of the American Association of Cancer Research. Anaheim, California, April 2005.
Engelhard HH: Treating Anaplastic Astrocytomas and Glioblastoma. Presented at “Sharing Hope” - the American Brain Tumor Association Symposium. Itasca, Illinois, July 2005.
Engelhard HH: Convection-Enhanced Delivery of a Histone Deacetylase Inhibitor Delays Progression of Malignant Gliomas in vivo. Presented at the International Tumor Metabolism Summit. Genova, Italy, October 2005.
(download pdf file of poster)
Engelhard HH, Porter KR, Barua M, Barker F: Clinical Presentation, Histology and Treatment of Patients with Primary Intraspinal Tumors. Presented at the Annual Meeting of the Congress of Neurological Surgeons. Boston, Massachusetts, October 2005.
Engelhard HH III, Porter KR, Stewart AK, Olson JJ for the Commission on Cancer Brain Tumor PCE Subcommittee. Overview of the results of the Commission on Cancer’s Central Nervous System (CNS) Tumor Patient Care Evaluation Study. Presented at the Annual Meeting of the American Association of Cancer Research. Orlando, Florida, March 2004.
Hahn YS, Herrera S, Engelhard H, Hamarti M: A New Insight on the Evolution of Growing Skull Fracture: Evidence Based on MRI, and CT Scan with 3D Reformation. Presented at the Annual Meeting of the Congress of Neurological Surgeons. San Francisco, California, October 2004.
Engelhard HH III, Porter KR, Barker FG II: Results from the Brain Tumor Patient Care Evaluation Study: Clinical Presentation and Patterns of Care. Presented at the Annual Meeting of the Society of Neuro-Oncology. Toronto, Canada, November 2004.
Engelhard HH, Alkan S, Duncan HA, Thomas C, Lee JM: NFkB, p65(RelA), is Commonly Expressed by Gliomas and Essential for Glioma Cell Survival. Presented at the Annual Meeting of the American Association of Neurological Surgeons. San Diego, California, April 2003.
Engelhard HH, Juarez A, Mix M, Duncan H, Vasoya H, Gemeinhart R: A New Human Glioblastoma Cell Line That Is Tumorigenic in Nonimmunosuppressed Rats. Presented at the Annual Meeting of the American Association of Neurological Surgeons. San Diego, California, April 2003.
Engelhard HH: Histone Deacetylase Inhibitors for Malignant Glioma: In Vivo Studies. Presented at the Second International Congress on Targeted Therapies in Cancer. Washington, D.C., August 2003.
Engelhard HH, Juarez A, Duncan H, Gemeinhart R: Characteristics of a Human Glioblastoma Cell Line Which Is Tumorigenic in Immunocompetent Rats. Presented at the Annual Meeting of the Society of Neuro-Oncology. Keystone, Colorado, November 2003.
Full list of Presentations (National, International and Regional Scientific Presentations) pdf document